We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Expert Opinion / Cases · January 18, 2021

Management of Rare RCC Subtypes - Translocation RCC

Written by
Nazli Dizman MD


Additional Info

Disclosure statements are available on the authors' profiles:

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • elvina almuradova

    Xp11.2 translocation renal cell carcinomas, mutated TFE3 gene leads to upregulation of the mesenchymal-epithelial transition (MET) Thus met inhibitors can be used in treatment

  • Apr 11, 2021

    Pending Moderator approval.

Further Reading